Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Infectious Disease
•
General Infectious Disease
•
Internal Medicine
Do you use metronidazole twice daily dosing for routine anaerobic coverage such as non-CNS, H. pylori, C. diff, or parasitic infections?
Related Questions
Would you consider use of doxycycline for deep-seated pasteurella multicoda infection in a patient with contraindications to first-line antimicrobial agents?
In a patient with CIED lead infection and bacteremia who had blood cultures cleared before CIED extraction, do we still need 72 hrs of documented negative blood cultures obtained post extraction to consider reimplantation and can we do same-time extraction and reimplantation?
How do you manage recurrent C diff which occurs shortly after FMT when alternate etiologies of diarrhea have been excluded and patient is responding to C diff-directed therapies?
Do you routinely recommend transition to dual PO antibiotic coverage for strep species and MRSA, for patients with purulent cellulitis and in the absence of culture data?
Do routinely recommend antifungal prophylaxis for non-transplant patients who have been diagnosed and completed treatment for possible/probable pulmonary aspergillosis and who will need varying degrees of ongoing immunosuppression?
Do you routinely use oral vancomycin prophylaxis in patients with a history of CDI who are receiving antibiotics?
In what situations do you recommend secondary prophylaxis for Nocardia after completion of treatment?
Do you treat with antibiotics active against methicillin-resistant staphylococci when a patient's culture grows non-lugdunensis, coagulase-negative staphylococci that tests susceptible to oxacillin by phenotypic testing, given the low constitutive PbP2A production of most CoNS?
What do you think about chronic suppressive therapy for HSV-2 in a patient with positive antibodies but no prior clinical outbreak?
What factors should be prioritized when deciding the timing of CIED extraction in patients with high surgical risk or multiple comorbidities?
